Scoparic Acid B

Scoparic Acid B

SCHEMBL14554122

C=C1C[C@@H](OC(=O)c2ccccc2)C2[C@](C)(C(=O)O)CCC[C@]2(C)[C@@H]1CCC(C)=O

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
TRPC6 Q9Y210 3/20 0.41
TRPC3 Q13507 1/20 0.40
PTPN1 P18031 1/20 0.38
PRKCA P17252 1/20 0.35
POLB P06746 1/20 0.34
HSD11B1 P28845 1/20 0.33
GAA P10253 1/20 0.33
TTL Q8NG68 3/20 0.33
TSHR P16473 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Scoparic Acid B SCHEMBL30621452 1.00 MAPT (0.43) MAPTMEN1LMNATP53CYP3A4
Scoparic Acid A SCHEMBL16610421 0.89 MAPT (0.42) MAPTMEN1LMNATP53CYP3A4
Scoparic Acid A SCHEMBL30621453 0.89 MAPT (0.42) MAPTMEN1LMNATP53CYP3A4
Scoparic Acid A SCHEMBL31051329 0.89 MAPT (0.42) MAPTMEN1LMNATP53CYP3A4
Scoparic Acid C SCHEMBL16610413 0.89 MAPT (0.41) MAPTMEN1LMNATP53CYP3A4
Scoparic Acid C SCHEMBL30621454 0.89 MAPT (0.41) MAPTMEN1LMNATP53CYP3A4
SCHEMBL16606704 0.86 TP53 (0.43) MAPTMEN1LMNATP53CYP3A4
SCHEMBL14552920 0.86 TP53 (0.43) MAPTMEN1LMNATP53CYP3A4
Scopadiol SCHEMBL16610408 0.79 TTL (0.44) MAPTMEN1LMNATP53CYP3A4
SCHEMBL31051333 0.78 TTL (0.43) MAPTMEN1LMNATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE Humanitas Technology, LLC (US) 2015-04-02 US disclosed
US-20130012470-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE Humanitas Technology, LLC (US) 2013-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012470-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE EIF2AK2, MAVS, DHX36 MAPT 3474/4885MEN1 4656/4885LMNA 2308/4885
US-20150093371-A1 ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE DDX5, MAVS, EIF2AK2 MAPT 4177/4885MEN1 4698/4885LMNA 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.